Pulmonary Fibrosis Therapeutic And Drug Pipeline Review H2

WiseGuyReports.com adds “Pulmonary Fibrosis - Pipeline Review, H1 2016” reports to its database.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/464940-pulmonary-fibrosis-pipeline-review-h1-2016-fibrosis-pipeline-review-h1-2016

The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
- The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Pulmonary Fibrosis Overview 11
Therapeutics Development 12
Pipeline Products for Pulmonary Fibrosis - Overview 12
Pipeline Products for Pulmonary Fibrosis - Comparative Analysis 13
Pulmonary Fibrosis - Therapeutics under Development by Companies 14
Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 20
Pulmonary Fibrosis - Pipeline Products Glance 21
Clinical Stage Products 21
Early Stage Products 22
Pulmonary Fibrosis - Products under Development by Companies 23
Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 30
Pulmonary Fibrosis - Companies Involved in Therapeutics Development 31
AdAlta Pty Ltd. 31
Advinus Therapeutics Ltd. 32
Aeolus Pharmaceuticals, Inc. 33
Afferent Pharmaceuticals, Inc. 34
AnaMar AB 35
Angion Biomedica Corp. 36
Antitope Limited 37
aTyr Pharma, Inc. 38
Biogen, Inc. 39
Bioneer Corporation 40
BiOrion Technologies B.V. 41
Bristol-Myers Squibb Company 42
Carolus Therapeutics, Inc. 43
Celgene Corporation 44
Chong Kun Dang Pharmaceutical Corp. 45
Clanotech AB 46
Compugen Ltd. 47

Access Report @ https://www.wiseguyreports.com/reports/464940-pulmonary-fibrosis-pipeline-review-h1-2016-fibrosis-pipeline-review-h1-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349
Website: http://www.wiseguyreports.com

Release ID: 149508